Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusing on their sensitivity to 1LCT. We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamoto, Shogo, Watanabe, Junichiro, Ohtani, Shoichiro, Morita, Satoshi, Ikeda, Masahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563944/
https://www.ncbi.nlm.nih.gov/pubmed/34728668
http://dx.doi.org/10.1038/s41598-021-00711-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563944/
https://www.ncbi.nlm.nih.gov/pubmed/34728668
http://dx.doi.org/10.1038/s41598-021-00711-x

Ejemplares similares